- 1 Title: Association of Nirmatrelvir/Ritonavir treatment and COVID-19 neutralizing antibody titers
- 2 in a longitudinal healthcare worker cohort
- 3
- 4 Slade Decker, BS²
- 5 Shaoming Xiao, MSPH²
- 6 Carly Dillen, PhD³
- 7 Christina M. Schumacher, PhD, MHS²
- 8 Aaron M. Milstone, MD, MHS^{1,2}
- 9 Matthew Frieman, PhD³
- 10 Amanda K. Debes, PhD, MS¹
- ¹ Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
- 12 ² Johns Hopkins University School of Medicine, Baltimore, MD, USA
- ³ Center for Pathogen Research, Department of Microbiology and Immunology, University of
- 14 Maryland School of Medicine, Baltimore MD 21212
- 15

16 Correspondence:

- 17 Amanda K. Debes PhD, MS
- 18 Department of International Health
- 19 615 N. Wolfe Street, E5036
- 20 Baltimore, MD 21205
- 21 adebes1@jhu.edu
- 22
- 23 Manuscript Word Count: 1386
- 24
- 25
- 26

27 Abstract

28	Nirmatrelvir/Ritonavir (NMV/r) is used for the treatment of COVID-19 infection. However,
29	rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing
30	antibodies to the SARS-CoV-2 spike protein before and after infection in people who did and did
31	not take NMV/r to determine if NMV/r impedes the humoral immune response.
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	

53 Introduction

54 In 2021, the Unites States Food and Drug Administration granted Emergency Use 55 Authorization to Nirmatrelvir/Ritonavir (NMV/r) for the treatment of mild-to-moderate COVID-19 56 infection. Soon after, the United States began providing anti-viral medication at no cost to 57 patients to reduce COVID-19 related hospitalizations and mortality. Reports then emerged of rebound COVID-19 infections, defined as detectable viremia and/or symptoms, two to eight 58 59 days after completing NMV/r treatment [1-3]. One hypothesis to explain post-treatment rebound 60 infection is that early viral suppression reduces the immune response, including antibody 61 production, thereby predisposing to recurrent viremia and symptoms [4-6]. Prior studies have found that for other viruses, in addition to SARS-CoV-2, early viral suppression can weaken 62 immune response to infection [4-5]. Our objective was to examine neutralizing antibodies to the 63 64 SARS-CoV-2 spike protein before and after infection in people who did and did not complete an 65 NMV/r treatment course to elucidate whether NMV/r impedes humoral immune response to SARS-CoV-2. 66

67 Methods

68 Study Population

69 Healthcare workers (HW) were consented into an ongoing seroprevalence cohort beginning in 70 June 2020. Approximately every two to six months, HW provided serum samples and completed 71 surveys that captured data including COVID-19 infection dates and NMV/r use. We measured 72 changes in neutralization antibody levels using pre-/post-infection serum samples from each 73 individual meeting inclusion criteria and compared changes in neutralization antibody levels by 74 NMV/r use. HW who received NMV/r (treated) were matched to a HW who did not (untreated). Inclusion criteria included: 1) COVID-19 infection (positive PCR or antigen test); 2) no prior 75 76 infection or receipt of vaccine dose within 90 days of pre-infection serum collection; 3) had 77 serum collected and stored within 90 days before infection, 4) had serum collected and stored at least 10 days post-infection. Treated HW were matched to untreated HW who had: 1) an
infection date +/- 14 days of a treated HW; and 2) dates of both the pre- and post-infection
serum collection were +/- 7 days of the treated HW serum collection. This study was approved
by the Johns Hopkins University institutional review board.

82 *Neutralization assay*

Neutralizing antibody titers to the spike protein of SARS-CoV-2 (WA-1) for pre- NMV/r and post-83 84 NMV/r (treated) samples were compared with untreated controls to determine if NMV/r had a 85 measurable response on neutralizing antibody response to infection. For the neutralization titer 86 assays (NT), serum samples were heat inactivated at 56°C for 30 min to remove complement and allowed to equilibrate to room temperature prior to processing for neutralization titer. 87 Samples were diluted in duplicate to an initial dilution of 1:10 followed by 1:2 serial dilutions 88 89 resulting in a 12-dilution series with each well containing 100mL. All dilutions were performed in 90 DMEM (Quality Biological), supplemented with 10% (v/v) fetal bovine serum (heat inactivated, 91 Sigma), 1% (v/v) penicillin/streptomycin (Gemini Bio-products) and 1% (v/v) L-glutamine (2 mM 92 final concentration, Gibco). Dilution plates were then transported into the BSL-3 laboratory and 93 SARS-CoV-2-GFP inoculum was added to each well to result in a multiplicity of infection (MOI) 94 of 0.01 upon transfer to tittering plates. A non-treated, virus-only control and a mock infection 95 control were included on every plate. The sample/virus mixture was then incubated at 37°C 96 (5.0% CO2) for 1 hour before transferring to 96-well flat bottom plates with confluent Vero-TMPRSS2 cells. Titer plates were incubated at 37°C (5.0% CO2) for 24 hours after cells were 97 98 fixed with 10% neutral buffered formalin (Sigma) for at least 1 hour at 4°C as per BSL3 SOP. Plates were removed from the BSL3 and stained with Hoechest 33342 (Thermo Scientific) 99 diluted 1:2000 in PBS for 10 minutes. Cells were washed with PBS and imaged with a Celigo 100 101 high content imager (Nexcelom).

102 Statistical analyses

The ratio of the half maximal inhibitory concentration (IC50) between matched participants preand post-infection were compared using Wilcoxon signed rank test. Statistical significance was defined as p < 0.05. Analyses were performed in R, version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria).

107 **Results**

Of 1353 HW who reported COVID-19 infection, 65 reported NMV/r use, and 32 met inclusion criteria from which 21 could be matched to a control. We performed neutralization assays on serum from 21 HW treated and 21 untreated with NMV/r. Of the 42 participants, the majority were female (86%) and White (90%). Treated participants were older (median: 50.9; IQR: 44.6-62.0 years) and less frequently female (78% vs. 94%) than untreated participants (median: 35.5; IQR: 32.6-40.9). Treated and untreated participants did not substantially differ by pre-existing conditions or prior exposure to SARS-CoV-2 spike protein.

115 The pre-infection and post-infection half maximal inhibitory concentrations (IC50) in the 116 treated group were lower than in the untreated group (Figure 1A). The median (IQR) NT of the 117 treated group pre- and post-infection was 980.0 (477.3-2720.3) and 4394.0 (1986.4-7608.4), 118 respectively (Supplemental Table). The median (IQR) NT of the untreated group pre- and post-119 infection was 1247.5 (433.0, 2032.7) and 7316.0 (4335.0, 10834.0) respectively (Supplemental 120 Table). Of the treated and untreated groups, 67% and 61%, respectively, had an NT greater 121 than or equal to 800 pre-infection, and 100% of both groups had an NT greater than or equal to 800 post-infection. The ratio of IC50 between the treated and untreated groups pre- and post-122 infection were similar (median: 0.64 and 0.76, respectively, p = 0.7) (Figure 1B). 123 124 Discussion

125 This study demonstrates that taking NMV/r after COVID-19 infection does not impact the 126 host humoral immune response. Our results show that the range between pre-infection and 127 post-infection neutralizing antibody titers for the treated and untreated groups was nearly 128 identical, with median ratios in IC50 values of 0.64 and 0.76, respectively. While this study demonstrates that there is no significant difference in post-infection NT between treated and
untreated groups, it highlights that despite high pre-infection NTs, both groups were still
infected. Other researchers have attempted to create clarity on the NT threshold of protection,
but it remains poorly defined [7].

133 Our goal was to see if NMV/r has an impact on host humoral immune response during 134 COVID-19 infection and we assessed this by comparing increase of neutralizing antibodies pre-135 to post-infection. A recent publication accessing immunoglobulin G (IgG) and Omicron-specific 136 neutralizing antibodies in individuals taking NMV/r using only post-infection data reported similar 137 findings, including similar neutralizing antibody levels when taking the medication and when not, with an overall conclusion that NMV/r treatment does not impact adaptive immune response [8]. 138 Our results suggest that concern about early viral suppression reducing immune response to 139 140 infection should not be a barrier or deterrent to taking NMV/r.

We believe the observed difference in age may be due to indication bias for treatment based on age; older age has been associated with higher risk for severe COVID-19 infection, leading to an increase in older individuals taking NMV/r. The difference in pre-infection and post-infection NT between the treated and untreated groups may be attributed to the age differences across study groups. Prior work has found that compared to older people, younger people produce a higher antibody response to COVID-19 [9-10].

Limitations of this study include a small sample size (n = 42), and a demographically homogenous cohort of HW that limits generalizability, although our sample size is significantly larger than those used in a similar prior study [8]. Secondly, we only performed NT on WA-1 SARS-CoV-2. Despite the antigenic differences between original SARS-CoV-2 and its numerous variants, including Omicron, we tested only WT WA1 strain as that is an identical match to the vaccine strain. Our study population consisted entirely of vaccinated individuals, so using the same strain as the vaccine would result in the most robust responses. 154 The results of this study show that NMV/r medication does not have a significant impact on humoral immune response post-infection. This finding should reassure those infected with 155 156 COVID-19 that they can take NMV/r without negatively impacting their humoral immune 157 response. More work is needed to break down barriers that have prevented the acceptance of 158 this drug as an important treatment option for COVID-19. This study examined immune 159 response relatively soon after infection; future research is needed to examine the impact of 160 rebound COVID-19 infections on neutralizing antibody titers, and the rate of anti-SARS-CoV-2 161 antibody degradation in individuals who take NMV/r compared to those who do not over longer 162 time periods post-infection. Our findings demonstrate that those at high-risk can take NMV/r to reduce the severity and length of mild to moderate COVID-19 infection without detriment to their 163 164 post-infection humoral immune response.

165

166 Acknowledgements: The authors would like to thank Annie Kuh, LuAnn Rezavi, and other 167 members of the Johns Hopkins Hospital Clinical Immunology Laboratory, Danielle Koontz, 168 Anushree Aneja and Emily Egbert of the Johns Hopkins Division of Pediatric Infectious 169 Diseases, and Matt Courtemanche from the Johns Hopkins University School of Medicine. We 170 would also like to thank Dr. Ralph Baric (UNC Chapel Hill) for providing the SARS-CoV-2-GFP 171 inoculum. Research reported in this publication was supported in part by the National Institute of 172 Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award number K24AI141580 (A.M.), HHSN272201400008C / 0258-0686-4609 (MF and CD), and the 173 174 generosity of the collective community of donors to the Johns Hopkins University School of 175 Medicine and the Johns Hopkins Health System for Covid-19 research. 176 177 Conflict of Interest Disclosure: All authors report no conflicts.

178

179 References

- 1. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. Covid-19 rebound after 180 Paxlovid and molnupiravir during January-June 2022. medRxiv [Preprint]. June 22, 2022 181 [cited 2023 March 09]. Available from: https://doi.org/10.1101/2022.06.21.22276724. 182
- 2. Wang L, Volkow ND, Davis PB, Berger NA, Kaelber DC, Xu R. Covid-19 rebound after 183

Paxlovid treatment during Omicron Ba.5 vs ba.2.12.1 subvariant predominance period.

- medRxiv [Preprint]. August 06, 2022 [cited 2023 Mar 9]. Available from:
- 186 https://doi.org/10.1101/2022.08.04.22278450
- 3. Boucau J, Uddin R, Marino C, et al. Characterization of Virologic rebound following 187
- Nirmatrelvir-Ritonavir treatment for coronavirus disease 2019 (covid-19). Clin Infect Dis, 188
- 189 **2022**; 76: 526–529.

184

185

- 190 4. Charness ME, Gupta K, Stack G, et al. Rebound of SARS-CoV-2 Infection after 191 Nirmatrelvir-Ritonavir Treatment. N Engl J Med, 2022; 387:1045-1047.
- 192 5. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus
- 193 infection: balancing virus clearance and immunopathology. Semin Immunopathol, 2016; 38: 71-82. 194
- 195 6. Rubin R. From positive to negative to positive again-the mystery of why COVID-19 196 rebounds in some patients who take Paxlovid. JAMA, **2022**; 327: 2380-2382.
- 7. Khoury DS, Schlub TE, Cromer D, et al. Correlates of Protection, Thresholds of 197
- 198 Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerg 199 Infect Dis, 2023; 29: 381-388.
- 8. Epling BP, Rocco JM, Boswell KL, et al. Clinical, Virologic, and Immunologic evaluation 200 of symptomatic coronavirus disease 2019 rebound following Nirmatrelvir/Ritonavir 201 202 treatment. Clin Infect Dis, 2023; 76: 573-581.
- 203 9. Vassilaki N, Gargalionis NG, Bletsa A, et al. Impact of Age and Sex on Antibody
- Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek 204
- 205 Healthcare Workers. Microorganisms, 2021; 9: 1725.

206	10. Shapiro JR, Sitaras I, Park H, et al. Association of Frailty, Age, and Biological Sex with
207	Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced
208	Immunity in Older Adults. Clin Infect Dis, 2022; 75: 61-71.
209	

Figure 1. Antibody response to SARS-CoV-2 by NMV/r use among unmatched and

- 211 matched pairs. Panel A: IC50 pre-infection and post-infection among unmatched participants
- who took NMV/r (n = 21) and those who did not (n = 21). IC50 values are displayed using a log (n = 21)
- scale of 10. Panel B: IC50 ratio of matched participants who took NMV/r versus those who did
- not measured between pre-infection and post-infection serum samples (n = 21). The dashed
- line represents an equivalent IC50 value (IC50 ratio = 1). IC50 ratio values are displayed using
- a log scale of 2.

